Does Lurbinectedin Cause Hair Loss?
Lurbinectedin ( Zepzelca), approved for metastatic small cell lung cancer, lists alopecia (hair loss) as a common side effect in clinical trials, occurring in 22-35% of patients depending on the study dose and combination therapy.[1][2] It's typically mild to moderate (Grade 1-2) and reversible after treatment ends, but not all patients experience it.
What Influences Hair Loss Severity?
Hair loss risk rises with:
- Higher doses: Phase 2 trials showed alopecia in 35% at 3.2 mg/m² monotherapy vs. lower rates at reduced doses.[2]
- Combination regimens: More frequent (up to 42%) when paired with doxorubicin or other chemotherapies, as these amplify toxicity.[1][3]
- Treatment cycles: Cumulative exposure over multiple cycles (e.g., 21-day cycles) increases incidence, with peak effects after 2-4 months.[2]
No specific patient demographics like age, sex, or ethnicity strongly predict it in trial data.
Are There Patient-Specific Risk Factors?
Limited data identifies these amplifiers:
- Prior chemotherapy: Patients with previous platinum-based regimens (common in small cell lung cancer) report higher rates, likely due to compromised hair follicles.[3]
- Baseline low hemoglobin or poor performance status: Correlates with overall toxicity, including alopecia, in relapsed patients.[2]
- Genetic factors: Not well-studied for lurbinectedin, but general chemotherapy hair loss links to variations in genes like GSTP1 (detoxification enzyme), though unconfirmed here.[4]
How Does It Compare to Other Lung Cancer Drugs?
| Drug | Alopecia Rate | Notes |
|------|---------------|-------|
| Lurbinectedin | 22-42% | Dose-dependent; mostly non-scalp. [1] |
| Topotecan (chemo alternative) | 15-20% | Similar mild profile. [3] |
| Irinotecan | 30-50% | Higher scalp involvement. [4] |
| Immunotherapies (e.g., atezolizumab) | <5% | Rare, immune-related. [3] |
Lurbinectedin's rate sits mid-range for second-line small cell therapies.
Prevention and Management Tips Patients Search For
- Scalp cooling: Reduces risk by 50% in some chemo studies; trials for lurbinectedin ongoing but promising.[4]
- Dose adjustments: Providers lower doses for Grade 2+ alopecia per prescribing info.[1]
- Supplements: Biotin or minoxidil lack strong evidence; consult oncologist to avoid interactions.
Hair regrows 1-3 months post-treatment in most cases.[2]
Clinical Trial Data Breakdown
IMforte (Phase 2): 35% alopecia at full dose.[2]
ATLAS (Phase 3, with irinotecan): 22%.[3]
Real-world studies confirm similar rates, with 5-10% Grade 3 (severe).[5]
[1]: Zepzelca Prescribing Information, Jazz Pharmaceuticals (fda.gov link).
[2]: Trigo et al., Lancet Oncology 2020 (lurbinectedin monotherapy trial).
[3]: ATLAS trial, JTO 2023.
[4]: Rugo et al., scalp cooling meta-analysis, JAMA Oncol 2017.
[5]: Farago et al., real-world data, Lung Cancer 2022.